| Literature DB >> 27316508 |
Jyotdeep K Raina1, Minakashee Sharma1, Rakesh K Panjaliya1, Minakshi Bhagat2, Ravi Sharma3, Ashok Bakaya4, Parvinder Kumar5.
Abstract
AIM: Potent risk factors at both genetic and non-genetic levels are accountable for susceptibility and instigation of different cardiovascular phenotypes. Recently, homocysteine is being identified as an important predictor for cardiovascular diseases. Homocysteine remethylation plays a key role in the synthesis of methionine and S-adenosine methionine. Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MTR) genes are known to regulate the homocysteine remethylation reaction and higher homocysteine level is significantly associated with diverse cardiovascular phenotypes. In this context, we aimed to carry out a study on the association of MTHFR (C677T) and MTR (A2756G) gene polymorphism with CVD in population of Jammu region of J&K state.Entities:
Keywords: CVD; MTHFR; MTR; Polymorphism
Mesh:
Substances:
Year: 2016 PMID: 27316508 PMCID: PMC4912384 DOI: 10.1016/j.ihj.2016.02.009
Source DB: PubMed Journal: Indian Heart J ISSN: 0019-4832
Fig. 1Showing the restriction digestion of MTR PCR product with HaeII enzyme. Lane no. 1 – marker, Lanes 2, 3, 6 and 7 – homozygous wild, Lanes 4 and 5 – heterozygous.
Fig. 2Showing the restriction digestion of MTHFR PCR product with HinfI enzyme. Lane no. 9 – marker, Lanes 1, 2, 3, 5, 6 and 8 – homozygous wild, Lanes 4 and 7 – heterozygous.
Prevalence of CVD risk factors in study groups.
| Parameters | Patients | Controls | OR | 95% CI | |||||
|---|---|---|---|---|---|---|---|---|---|
| Men ( | Women ( | Total ( | Men ( | Women ( | Total ( | ||||
| Age (years) | 58.98 ± 15.08 | 53.40 ± 13.94 | 57.06 ± 14.90 | 42.03 ± 12.58 | 41.73 ± 12.51 | 41.91 ± 12.53 | – | – | – |
| Dwelling | |||||||||
| Urban | 61 (47.66%) | 24 (35.82%) | 85 (43.59%) | 28 (19.31%) | 25 (26.31%) | 53 (22.08%) | – | – | – |
| Sub-urban | 49 (38.28%) | 23 (34.33%) | 72 (36.92%) | 65 (44.83%) | 41 (43.16%) | 106 (44.17%) | – | – | |
| Rural | 18 (14.06%) | 20 (29.85%) | 38 (19.49%) | 52 (35.86%) | 29 (30.53%) | 81 (33.75%) | – | ||
| Physical activity | |||||||||
| Performers | 67 (52.34%) | 23 (34.33%) | 90 (46.15%) | 102 (70.34%) | 60 (63.16%) | 162 (67.5%) | Ref | ||
| Sedentary | 61 (47.66%) | 44 (65.67%) | 105 (53.85%) | 43 (29.66%) | 35 (36.84%) | 78 (32.5%) | 2.42 | <0.0001 | 1.64–3.58 |
| Smoking | |||||||||
| Current | 25 (19.53%) | 1 (1.5%) | 26 (13.33%) | 34 (23.45%) | 2 (2.11%) | 36 (15%) | 1.09 | 0.76 | 0.63–1.89 |
| Formers | 38 (29.69%) | 1 (1.5%) | 39 (20%) | 8 (5.52%) | – | 8 (3.33%) | 7.35 | <0.001 | 3.33–16.23 |
| Non-smokers | 65 (50.78%) | 65 (97.0%) | 130 (66.67%) | 103 (71.03%) | 93 (97.89%) | 196 (81.67%) | Ref | ||
| Duration of smoking (years) | 24.51 ± 13.63 | 13.5 ± 9.19 | 24.17 ± 13.60 | 11.90 ± 13.82 | 30.5 ± 34.65 | 12.75 ± 15.01 | – | – | – |
| Alcohol intake | |||||||||
| Current | 43 (33.59%) | – | 43 (22.05%) | 27 (18.62%) | – | 27 (11.25%) | 2.49 | 0.0007 | 1.47–4.22 |
| Former | 16 (12.5%) | – | 16 (8.21%) | – | – | – | – | – | – |
| Never | 69 (53.91%) | 67 (100%) | 136 (69.74%) | 118 (81.38%) | 95 (100%) | 213 (88.75%) | Ref. | ||
| Duration of alcohol intake (years) | 22.12 ± 14.55 | – | 21.14 ± 13.75 | 9.07 ± 5.05 | – | 9.07 ± 5.05 | – | – | – |
| Diet pattern | |||||||||
| Vegetarian | 25 (19.53%) | 33 (49.25%) | 58 (29.74%) | 52 (35.86%) | 55 (57.89%) | 107 (44.58%) | Ref | ||
| Non-vegetarian | 103 (80.47%) | 34 (50.75%) | 137 (70.26%) | 93 (64.14%) | 40 (42.11%) | 133 (55.42%) | 1.90 | 0.002 | 1.27–2.83 |
| History of HTN | |||||||||
| Yes | 81 (63.28%) | 31 (46.27%) | 112 (57.44%) | – | – | – | – | <0.0001 | – |
| No | 47 (36.72%) | 36 (53.73%) | 83 (42.56%) | – | – | – | – | ||
| History of DM | |||||||||
| Yes | 25 (19.53%) | 13 (19.40%) | 38 (19.49%) | – | – | – | – | 0.0001 | – |
| No | 103 (80.47%) | 54 (80.60%) | 157 (80.51%) | – | – | – | |||
HTN, hypertension; DM, diabetes mellitus.
Significant values.
Physiometric, anthropometric and biochemical variables in the study groups.
| Parameters | Patients | Controls | |||||
|---|---|---|---|---|---|---|---|
| Men ( | Women ( | Total ( | Men ( | Women ( | Total ( | ||
| Blood pressure (mmHg) | |||||||
| Systolic (SBP) | 143.75 ± 19.53 | 138.19 ± 23.66 | 141.84 ± 21.15 | 125.45 ± 7.31 | 122.73 ± 7.94 | 124.37 ± 7.67 | <0.0001 |
| Diastolic (DBP) | 88.63 ± 9.46 | 87.04 ± 10.58 | 88.09 ± 9.86 | 86.04 ± 10.16 | 83.82 ± 8.74 | 85.16 ± 9.67 | 0.002 |
| Pulse pressure (PP) | 55.19 ± 15.72 | 51.15 ± 18.03 | 53.80 ± 16.62 | 39.41 ± 8.93 | 38.90 ± 6.73 | 39.21 ± 8.12 | <0.0001 |
| Pulse rate (PR) | 80.53 ± 11.38 | 85.12 ± 17.34 | 82.11 ± 13.85 | 73.43 ± 4.16 | 72.94 ± 2.76 | 73.24 ± 3.67 | <0.0001 |
| BMI | 24.11 ± 4.30 | 24.67 ± 5.65 | 24.30 ± 4.80 | 23.01 ± 3.80 | 22.46 ± 4.50 | 22.79 ± 4.07 | 0.0004 |
| WHR | 1.00 ± 0.07 | 0.99 ± 0.10 | 1.00 ± 0.08 | 0.95 ± 0.05 | 0.95 ± 0.05 | 0.95 ± 0.05 | <0.0001 |
| Total cholesterol (TC) (mg/dl) | 184.26 ± 58.85 | 185.30 ± 65.23 | 184.62 ± 60.95 | 131.44 ± 31.17 | 124.82 ± 31.67 | 128.82 ± 31.47 | <0.0001 |
| Triglycerides (TG) (mg/dl) | 207.95 ± 86.16 | 198.13 ± 71.69 | 204.58 ± 81.42 | 124.13 ± 26.75 | 122.04 ± 26.45 | 123.30 ± 26.6 | <0.0001 |
| HDL-C (mg/dl) | 35.62 ± 9.95 | 37.24 ± 9.54 | 36.18 ± 9.82 | 50.81 ± 7.03 | 52.28 ± 6.25 | 51.39 ± 6.75 | <0.0001 |
| LDL-C (mg/dl) | 126.66 ± 69.75 | 135.76 ± 74.53 | 129.78 ± 71.37 | 78.26 ± 18.56 | 75.58 ± 20.37 | 77.20 ± 19.30 | <0.0001 |
Values are mean ± SD.
SBP, systolic blood pressure; DBP, diastolic blood pressure, BMI, body mass index; WHR, waist hip ratio, HDL, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
Significant values.
Genotypic and allelic allocation of MTHFR (C677T) and MTR (A2756G) polymorphism in study groups.
| Genotypes/alleles/genetic model | CVD cases ( | Controls ( | OR (95% CI) | |
|---|---|---|---|---|
| 677CC | 181 (92.82%) | 238 (99.17%) | 1 (Reference) | |
| 677 CT (CC vs CT) | 14 (7.18%) | 2 (0.83%) | 9.20 [2.06–41.01] | 0.00047 |
| 677 TT (CC vs TT) | 0 (0%) | 0 (0%) | Not possible | – |
| 677 CT + TT (CC vs CT + TT) | 14 (7.18%) | 2 (0.83%) | 9.20 [2.06–41.01] | 0.00047 |
| 677C | 0.96 | 0.996 | 1 (Reference) | |
| 677T (C vs T) | 0.04 | 0.004 | 8.89 [2.01–39.40] | 0.00053 |
| 2756AA | 81 (41.54%) | 131 (54.58%) | 1 (Reference) | |
| 2756AG (AA vs AG) | 110 (56.41%) | 109 (45.42%) | 1.63 [1.11–2.39] | 0.01 |
| 2756GG (AA vs GG) | 4 (2.05%) | 0 (0%) | Not possible | – |
| 2756AG + GG (AA vs AG + GG) | 114 (58.46%) | 109 (45.42%) | 1.69 [1.15–2.47] | 0.007 |
| 2756A | 0.7 | 0.8 | 1 (Reference) | |
| 2756G (A vs G) | 0.3 | 0.2 | 1.48 [1.09–2.00] | 0.01 |
OR and 95% CI were calculated with MTHFR 677CC and MTR 2756AA genotype as reference group.
Some genotype combinations were not observed, so it was not possible to calculate odds ratio.
Significant values.
Combined genotype frequencies of MTHFR and MTR gene polymorphisms in study groups.
| Variant MTHFR C677T/MTR A2756G | CVD cases ( | Controls ( | OR (95% CI) | |
|---|---|---|---|---|
| 677CC/2756AA | 73 (37.44%) | 130 (54.16%) | 1 (Reference) | |
| 677CT/2756AA | 8 (4.10%) | 1 (0.42%) | 14.25 [1.75–116.17] | 0.01 |
| 677TT/2756AA | 0 | 0 | Not possible | |
| 677CC/2756AG | 104 (53.33%) | 108 (45%) | 1.71 [1.16–2.54] | 0.007 |
| 677CT/2756AG | 6 (3.08%) | 1 (0.42%) | 10.68 [1.26–90.48] | 0.03 |
| 677TT/2756AG | 0 | 0 | Not possible | |
| 677CC/2756GG | 4 (2.05%) | 0 | Not possible | |
| 677CT/2756GG | 0 | 0 | Not possible | |
| 677TT/2756GG | 0 | 0 | Not possible |
Some genotype combinations were not observed, so it was not possible to calculate odds ratio.
Significant values.
MTHFR (C677 T) gene polymorphism in different ethnic groups.
| Ethnicity | Frequency of genotypes (%) | Frequency of alleles (%) | Type of CVD phenotype | Reference | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||||||||
| CC | CT | TT | CC | CT | TT | C | T | C | T | |||
| North Indian | 92.82 | 7.18 | 0 | 99.17 | 0.83 | 0 | 96.41 | 3.59 | 99.5 | 0.5 | CAD, MI, Arrhythmia | Present study |
| North Indian | 70.9 | 24.6 | 4.4 | 73.59 | 25 | 1.4 | 83.3 | 16.7 | 86.1 | 13.9 | CAD | Pandey et al. (2011) |
| East Indian | 51.6 | 21.6 | 26.72 | 72.94 | 14.11 | 12.9 | 61.96 | 38.03 | 63.97 | 36.12 | CAD | Dhar et al. (2010) |
| South Indian | 73.3 | 26.7 | 0 | 80 | 20 | 0 | 86 | 14 | 90 | 10 | MI and DM | Angeline et al. (2009) |
| Arabs | 64.2 | 32.1 | 3.7 | 72.2 | 25.8 | 2 | 80 | 20 | 85 | 15 | CAD | Abu-Amero et al. (2003) |
| Turkish | 48.7 | 40 | 11.3 | 55.9 | 40.7 | 3.4 | 69 | 31 | 76 | 24 | CAD | Caner et al. (2008) |
| Italian | 29.2 | 48.7 | 22.1 | 24.7 | 52.5 | 22.8 | 53.5 | 46.5 | 50.93 | 49.07 | Arrhythmia | Giusti et al. (2007) |
CAD, coronary artery disease; EH, essential hypertension; MI, myocardial infarction; DM, diabetes mellitus.
MTR (A2756G) gene polymorphism in different ethnic groups.
| Ethnicity | Frequency of genotypes (%) | Frequency of alleles (%) | Type of CVD phenotype | Reference | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||||||||
| AA | AG | GG | AA | AG | GG | A | G | A | G | |||
| North Indian | 41.54 | 56.41 | 2.05 | 54.58 | 45.52 | 0 | 69.74 | 30.26 | 77 | 23 | CAD, MI, Arrhythmia | Present study |
| South Indian | 94 | 6 | 0 | 210 | 0 | 0 | 97 | 3 | 100 | – | CAD | Kanth et al. (2011) |
| South Indian | 170 | 149 | 31 | 126 | 141 | 12 | 69.8 | 31.2 | 70.4 | 29.6 | CAD | Lakshmi (2011) |
| Chinese | 88.9 | 10.7 | 0.39 | 84.6 | 15 | 0.4 | 94.2 | 5.8 | 92.1 | 7.9 | Cerebrovascular diseases | Aifan et al. (2009) |
| Tunisian | 72 | 26.2 | 1.9 | 80.5 | 18.7 | 0.9 | 85 | 15 | 90 | 10 | MI | Jemaa et al. (2008) |
| Italian | 70 | 28 | 2 | 68.9 | 29 | 2.1 | 83.99 | 16.01 | 83.39 | 16.61 | Arrhythmia | Giusti et al. (2007) |
CAD, coronary artery disease; EH, essential hypertension; MI, myocardial infarction.